ArticleCancers2025
Dose-Guided Hybrid AI Model with Deep and Handcrafted Radiomics for Explainable Radiation Dermatitis Prediction in Breast Cancer VMAT.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo improve the prediction accuracy of radiation dermatitis (RD) in breast cancer patients undergoing volumetric modulated arc therapy (VMAT), we developed a hybrid artificial intelligence (AI) model that integrates deep learning radiomics (DLR), handcrafted radiomics (HCR), clinical features, and dose-volume histogram (DVH) parameters, aiming to enhance the early identification of high-risk individuals and support personalized prevention strategies.
methodsA retrospective cohort of 156 breast cancer patients treated with VMAT at Kaohsiung Veterans General Hospital (2018-2023) was analyzed; 148 patients were eligible after exclusions, with RD graded according to the RTOG criteria. Clinical variables and 12 DVH indices were collected, while HCR features were extracted via PyRadiomics. DLR features were derived from a pretrained VGG16 network across four input designs: original CT images (DLR
resultsAmong the 148 patients, 49 (33%) developed Grade ≥ 2 RD. The DLR models outperformed the HCR models (AUC = 0.72 vs. 0.66). The best performance was achieved with DLR
conclusionsThe proposed hybrid AI framework, which integrates DLR, clinical, and DVH features, provides accurate and explainable predictions of Grade ≥ 2 RD after VMAT in breast cancer patients. By combining ensemble learning with XAI methods, the model offers reliable high-risk stratification and potential clinical utility for personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.